Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Your Environment. Your Health.

Publication Detail

Title: A Small Molecule Targeting Mutagenic Translesion Synthesis Improves Chemotherapy.

Authors: Wojtaszek, Jessica L; Chatterjee, Nimrat; Najeeb, Javaria; Ramos, Azucena; Lee, Minhee; Bian, Ke; Xue, Jenny Y; Fenton, Benjamin A; Park, Hyeri; Li, Deyu; Hemann, Michael T; Hong, Jiyong; Walker, Graham C; Zhou, Pei

Published In Cell, (2019 06 27)

Abstract: Intrinsic and acquired drug resistance and induction of secondary malignancies limit successful chemotherapy. Because mutagenic translesion synthesis (TLS) contributes to chemoresistance as well as treatment-induced mutations, targeting TLS is an attractive avenue for improving chemotherapeutics. However, development of small molecules with high specificity and in vivo efficacy for mutagenic TLS has been challenging. Here, we report the discovery of a small-molecule inhibitor, JH-RE-06, that disrupts mutagenic TLS by preventing recruitment of mutagenic POL ζ. Remarkably, JH-RE-06 targets a nearly featureless surface of REV1 that interacts with the REV7 subunit of POL ζ. Binding of JH-RE-06 induces REV1 dimerization, which blocks the REV1-REV7 interaction and POL ζ recruitment. JH-RE-06 inhibits mutagenic TLS and enhances cisplatin-induced toxicity in cultured human and mouse cell lines. Co-administration of JH-RE-06 with cisplatin suppresses the growth of xenograft human melanomas in mice, establishing a framework for developing TLS inhibitors as a novel class of chemotherapy adjuvants.

PubMed ID: 31178121 Exiting the NIEHS site

MeSH Terms: Animals; Antineoplastic Agents/pharmacology; Antineoplastic Agents/therapeutic use*; Cell Line, Tumor; Cell Survival/drug effects; Cisplatin/adverse effects; Cisplatin/pharmacology; Cisplatin/therapeutic use*; DNA Damage/drug effects; Female; Gene Knockdown Techniques; Humans; Mad2 Proteins/metabolism; Mice; Mice, Nude; Mice, Transgenic; Mutagenesis/drug effects*; Neoplasms/drug therapy*; Neoplasms/metabolism; Neoplasms/pathology; Nucleotidyltransferases/antagonists & inhibitors; Nucleotidyltransferases/chemistry; Nucleotidyltransferases/genetics; Nucleotidyltransferases/metabolism; Quinolines/chemistry; Quinolines/pharmacology; Quinolines/therapeutic use*; Transfection; Tumor Burden/drug effects; Xenograft Model Antitumor Assays

Back
to Top